Samuel Wood, MD
Hematology & Oncology · Cedar Rapids, IANPI 1356387260
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $233 of the $337 with a category attached, or 69.3%. It is spread thinly across 12 manufacturers, the largest accounting for just 18.3%. That places this record below the midpoint for hematology & oncology clinicians in IA, where the typical reported total is $603.
Across 18 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$62
- AstraZeneca$58
- Bristol Myers Squibb$42
- Johnson & Johnson$29
- Gilead$29
- E.r. Squibb & Sons, L.L.C.$21
- plus $95 from 6 others
What the payments were for
- Food & beverage$23369%
- Education$10331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $62 |
| AstraZeneca | 2 | $58 |
| Bristol Myers Squibb | 2 | $42 |
| Johnson & Johnson(2 entities) | 2 | $29 |
| Gilead | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| Astellas Pharma US Inc | 1 | $14 |
| Merck | 1 | $14 |
| CTI Biopharma Corp. | 1 | $13 |
| AVEO Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$337 in reported general payments places this provider in the 40th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 29 | $707,675 |
| ImbruvicaIbrutinib | 38 | $646,398 |
| Lenalidomide | 39 | $474,810 |
| InlytaAxitinib | 16 | $330,863 |
| PomalystPomalidomide | 11 | $283,795 |
| RevlimidLenalidomide | 16 | $258,189 |
| XtandiEnzalutamide | 11 | $183,513 |
| Abiraterone Acetate | 70 | $177,700 |
| XareltoRivaroxaban | 109 | $96,567 |
| EliquisApixaban | 63 | $52,257 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 82 | $2,250 |
| Ondansetron Hcl | 62 | $1,684 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 48 | $1,548 |
| Hydroxyurea | 61 | $1,040 |
| Morphine Sulfate | 30 | $978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Eliquis | $20 | $383,12079 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $21 | $283,79511 claims |
| Bristol Myers SquibbRevlimid | $42 | $258,18916 claims |
| Astellas Pharma US IncXtandi | $14 | $183,51311 claims |
| Johnson & JohnsonXarelto | $29 | $96,567109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Cedar Rapids
- Rasa BuntinasCedar Rapids$1K
- William FusselmanCedar Rapids$848
- Chirantan GhoshCedar Rapids$105
- Sakeer HussainCouncil Bluffs$74K
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Kartik AnandWest Des Moines$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.